SANAMED
2024; 19(2): 181–189
ISSN-1452-662X

DOI: 10.5937/sanamed0-51480
UDK: 618.19-006.6-074:577.1
ID: 149810441
Original article

THE PROGNOSTIC AND PREDICTIVE VALUE OF KI-67 PROLIFERATION INDEX AND uPA/PAI-1 COMPLEX IN SERUM FOR PATIENTS WITH EARLY INVASIVE BREAST CANCER

Pušina Sadat,[1] Hodžić Edin,[1] Salibašić Mirhan,[1] Bičakčić Emir,[1] Herenda-Pušina Naida,[2] Halilović Emsad[1]

[1] Clinical Center University of Sarajevo, Clinic for General and Abdominal Surgery, Sarajevo, Bosnia and Herzegovina
[2] Clinical Center University of Sarajevo, Clinic for Anesthesiology and Reanimatology, Sarajevo, Bosnia and Herzegovina

Primljen/Received 06. 06. 2024. god. Prihvaćen/Accepted 22. 07. 2024. god.

Abstract: **Introduction:** Breast cancer, the most common malignancy in women, represents a significant health issue, and biomarkers such as the Ki-67 index and uPA/PAI-1 complex can provide insight into treatment outcomes and therapeutic response.

Objective: The primary outcome of the study was the assessment of 5-year disease-free survival (DFS), defined as the postoperative period until the occurrence of loco-regional or distant metastases and death from any cause.

Patients and Methods: A retrospective cohort study included 166 patients with early invasive breast cancer, in whom the prognostic and predictive significance of the uPA/PAI-1 complex and Ki-67 biomarkers in surgically treated patients at the Clinic for General and Abdominal Surgery of the University Clinical Center in Sarajevo was evaluated during the period from September 2015 to February 2017.

Results: Univariate regression analysis identified an increased probability of DFS shorter than five years in patients with negative hormone receptors, positive HER-2 receptor, ≥ 8 positively mph nodes, and a Ki-67 index ≥ 14% ($p < 0.05$). Multivariate regression analysis revealed that T2 stage, tumor size of 20-50 mm, and a Ki-67 index ≥ 14% were associated with a higher probability of DFS shorter than five years ($p < 0.05$). The five-year DFS rate was higher in patients with a Ki-67 index < 14% compared to those with ≥ 14% ($p = 0.011$), while there was no difference in five-year DFS among patients with different levels of the uPA/PAI-1 complex ($p = 0.636$).

Conclusion:Our study highlights the importance of the Ki-67 proliferative index as a strong prognostic and predictive factor for DFS in patients operated on for early invasive breast cancer. Additional monitoring and tailored therapeutic strategies may be beneficial in patients with elevated Ki-67 index values, T2 stage, and tumor size of 20-50 mm.

Keywords: biomarkers, general surgery, treatment outcome, women's health.

INTRODUCTION

Breast cancer is the most common cancer in women worldwide and represents a significant public health issue, being the fifth leading cause of cancer death in the developed world (1, 2).

Early invasive breast cancer, which includes stages T1, T2, N0, N1, and T3N0, can be genetically analyzed to classify into four main molecular subtypes: Luminal A, Luminal B, HER2-positive, and "basal-like" or "triple-negative" (3, 4). The Ki-67 antigen proliferative index, a marker of cell proliferation in breast cancer, shows positive protein expression in all phases of the cell cycle (except the G0 phase), with its elevated expression being associated with an increased risk of disease recurrence and a reduced response to systemic therapy (5).

However, due to the lack of standardized laboratory analysis methodology and clear cut-off values for the application of systemic therapy, the Ki-67 proliferative index has not yet been accepted as a universal biomarker for breast cancer prognosis (6).

The occurrence of metastasesis the main cause of mortality in breast cancer, with extracellular matrix degradation playing a key role in this process, facilitated

by the urokinase plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) complex (7, 8).

Due to its clinical relevance, the uPA/PAI-1 complex determined in tumor tissue or cytosol has been recognized as a prognostic and predictive biomarker for breast cancer, as confirmed by the recommendation of the American Society of Clinical Oncology (9).

In today's medical practice, increasing emphasis is placed on the prognostic-predictive value of genetic panels that play a key role in the individualization of treatment and improvement of treatment outcomes in various diseases, including breast cancer (10). However, in transitional countries, these genetic markers are not yet widely accepted and available in practice (11, 12, 13).

Existing short comings and controversies underscore the need to investigate the role of the Ki-67 proliferative index and uPA/PAI-1 complex in serum and their integration into the existing concept of prognosis and prediction in patients with early invasive breast cancer.

Aim

The aim of our studywas to investigate the prognostic and predictive significance of Ki-67 proliferative index values and preoperative levels of the uPA/PAI-1 complex in serum in patients operated on for early invasive breast cancer, to contribute to the improvement of their treatment efficacy.

PATIENTS AND METHODS

Our prospective-retrospective cohort study included 166 patients older than 18 years with pathologically verified early invasive breast cancer, surgically treated at the Department of General and Abdominal Surgery, Clinical Center of the University of Sarajevo (CCUS), from September 2015 to February 2017. This study was approved by the Ethical Committee of CCUS. All procedures were in accordance with the institutional and national research committee's ethical standards and with the 1964 Helsinki Declaration and its later amendments.

Patients without cutaneous manifestations of the disease and those without previous premalignant or malignant breast diseases were included. Additionally, patients with a negative history of immune, chemo, radio, and hormonal therapies, as well as those without previous breast or axillary lymph node surgeries, were included.

Patients with advanced forms of cancer, including infiltration and inflammation of the breast skin region, and those with multiple breast cancers were excluded from the study. Patients with systemic liver, kidney, or cardiovascular diseases, as well as those who didn't provide informed consent to participate in the study, were also excluded.

Surgical treatment involved radical modified mastectomies or breast-conserving surgeries. Furthermore, complete dissection of the first and second layers of ipsilateral axillary lymph nodes or sentinel lymph node biopsy was performed (14).

Laboratory tests were conducted at the Clinical Biochemistry with Immunology Department of CCUS. The preoperative concentration of the uPA/PAI-1 complex in serum ranged from 0.1 to 100 ng/ml according to the manufacturer's instructions (15).

Pathohistological analysis was performed at the Clinical Pathology, Cytology, and Human Genetics Department of CCUS. The thres hold value to distinguish "high" and "low" Ki-67 proliferation index was set at 14% (16).

Disease-free survival (DFS) was defined as the postoperative time until the occurrence of locoregional or distant metastases and death from any cause, expressed in months.

Patient follow-up included five-year monitoring through annual mammographic and clinical examinations, following the standard protocol for early invasive breast cancer (17).

IBM SPSS Statistics version 22.0 for Windows was used for statistical analysis. The Chi-square (X^2) test was used to examine the association between variables. Univariate and multivariate regression analyses were applied to assess the independent and adjusted effects of the predictors of DFS, respectively. Receiver operating characteristic (ROC) analysis was used to evaluate the discriminative power of uPA/PAI-1 markers in predicting DFS. Kaplan-Meier analysis was used to evaluate the assessment of five-year DFS according to Ki-67 index and uPA/PAI-1 complex values. The most important results were presented in the form of tables and figures.

RESULTS

Univariate regression analysis revealed that patients with negative estrogen receptors (OR = 2.89; p = 0.040; 95% CI: 1.050, 7.975), negative progesterone receptors (OR = 2.91; p = 0.022; 95% CI: 1.170, 7.261), positive human epidermal growth factor receptor 2 (HER-2) (OR = 0.349; p = 0.029; 95% CI: 0.136, 0.897), eight or more positive lymph nodes (OR = 0.148; p = 0.004; 95% CI: 0.041, 0.537), those without Luminal A tumors (OR = 3.67; p = 0.008; 95% CI: 1.410, 9.599), and a Ki-67 index ≥ 14% (OR = 3.301; p = 0.014; 95% CI: 1.117, 0.787) had a higher likelihood of DFS shorter than five years. No statistically significant association was found between other predictors and five-year DFS, as shown in Table 1.

Table 1. *Representation of predictors of five-year disease-free survival and the results of univariate regression analysis*

Variables		N (%)	5Y-DFS		P*	95% CI*
			Achieved 144 (86.7)	Not Achieved 22 (13.3)		
			N (%)	N (%)		
Age	< 45 years	19 (11.4)	16 (84.2)	3 (15.8)	0.729	(0.336; 4.747)
	45 years and above	147 (88.6)	128 (87.1)	19 (12.9)		
Menstrual status	Premenopause	25 (15.2)	22 (88.0)	3 (12.0)	0.832	(0.237; 3.185)
	Postmenopause	140 (84.8)	121 (86.4)	19 (13.6)		
Tumor stage	T1 stage	74 (44.6)	65 (87.8)	9 (12.2)	0.710	(0.338; 2.209)
	T2 stage	92 (55.4)	79 (85.9)	13 (14.1)		
Tumor size (mm)	0.1-19.9 mm	78 (47.0)	71 (91.0)	7 (9.0)	0.132	(0.185; 1.247)
	20-50 mm	88 (53.0)	73 (83.0)	15 (17.0)		
Estrogen receptor	Negative	27 (16-3)	20 (74.1)	7 (25.9)	0.040	(1.050; 7.975)
	Positive	139 (83.7)	124 (89.2)	15 (10.8)		
Progesteron receptor	Negative	54 (32.5)	42 (77.8)	12 (22.2)	0.022	(1.170; 7.261)
	Positive	112 (65.7)	102 (91.1)	10 (8.9)		
HER-2 receptor	Negative	129 (77.7)	116 (89.9)	13 (10.1)	0.129	(0.136; 0.897)
	Positive	37 (22.3)	28 (75.7)	9 (24.3)		
Lymph nodes	Negative	83 (50.0)	76 (91.6)	7 (8.4)	0.073	(0.161; 1.085)
	1-3 positive lymph nodes	51 (30.7)	43 (84.3)	8 (15.7)	0.539	(0.291; 1.906)
	4-7 positive lymph nodes	21 (12.7)	19 (90.5)	2 (9.5)	0.592	(0.329; 7.031)
	8 or more positive lymph nodes	11 (6.6)	6 (54.5)	5 (45.5)	0.004	(0.441; 0.537)
Molecular subtypes	Luminal A	98 (59.0)	91 (92.9)	7 (7.1)	0.008	(1.410; 9.599)
	Luminal B, HER-2 positive	16 (9.6)	14 (87.5)	2 (12.5)	0.926	(0.228; 5.097)
	Luminal B, HER-2 negative	25 (15.1)	19 (76.0)	6 (24.0)	0.093	(0.141; 1.164)
	HER-2 positive	9 (5.4)	6 (66.7)	3 (33.3)	0.085	(0.064; 1.193)
	Triple negative	18 (10.8)	14 (77.8)	4 (22.2)	0.243	(0.485; 1.634)
uPA/PAI-1 complex levels	0-0.99 ng/ml	35 (21.1)	29 (82.9)	6 (17.1)	0.203	(0.653; 1.258)
	1-1.99 ng/ml	93 (56.0)	80 (86.0)	13 (14.0)		
	2-2.99 ng/ml	33 (19.9)	30 (90.9)	3 (9.1)		
	3 ng/ml or above	5 (3.0)	5 (100)	0 (0.0)		
Ki-67 index	< 14%	144 (86.7)	119 (90.2)	13 (9.8)	0.014	(0.117; 0.787)
	14 % or above	34 (13.3)	25 (73.5)	9 (26.5)		

*Univariate regression analysis for 5Y-DFS

5Y-DFS, Five-year disease-free survival; CI, Confidence interval; HER-2, Human epidermal growth factor receptor 2; Ki-67, Antigen Kiel 67; uPA/PAI-1, Urokinase plasminogen activator/plasminogen activator inhibitor-1

Table 2. *Multivariate regression analysis of predictors of five-year disease-free survival*

		5Y-DFS*	
		P	95% CI
Age	< 45 years	0.564	(0.220; 6.053)
	45 years and above		
Menstrual status	Premenopause	0.585	(0.081; 4.128)
	Postmenopause		
Tumor stage	T1 stage	0.009	(1.991; 2.622)
	T2 stage		
Tumor size (mm)	0.1-19.9 mm	0.005	(0.007; 0.413)
	20-50 mm		
Estrogen receptor	Negative	0.994	(0.080; 2.773)
	Positive		
Progesteron receptor	Negative	0.961	(0.229; 4.057)
	Positive		
HER-2 receptor	Negative	0.508	(0.195; 2.244)
	Positive		
Lymph nodes	Negative	0.070	(0.957; 3.044)
	1-3 positive lymph nodes		
	4-7 positive lymph nodes		
	8 or more positive lymph nodes		
Molecular subtypes	Luminal A	0.366	(0.638; 3.387)
	Luminal B, HER-2 positive		
	Luminal B, HER-2 negative		
	HER-2 positive		
	Triple negative		
uPA-PAI-1 complex levels (ng/ml)	0-0.99 ng/ml	0.178	(0.239; 1.303)
	1-1.99 ng/ml		
	2-2.99 ng/ml		
	3 ng/ml or above		
Ki-67 index (%)	< 14%	0.031	(0.097; 1.152)
	14 % or above		

*Multivariate regression analysis for 5Y-DFS

5Y-DFS, Five-year disease-free survival; CI, Confidence interval; HER-2 receptor, Human epidermal growth factor receptor 2; Ki-67, Antigen Kiel 67; uPA/PAI-1, Urokinase plasminogen activator/plasminogen activator inhibitor-1

In multivariateregression analysis, patients with T2 stage tumors (OR = 0.302; p = 0.009; 95% CI: 1.991, 2.622), tumor size of 20-50 mm (OR = 0.304; p = 0.005; 95% CI: 0.007, 0.413), or Ki-67 index ≥ 14% (HR = 0.292; p = 0.031; 95% CI: 0.097, 1.152) had a significantly higher likelihood of DFS shorter than five years. Multivariate regression analysis did not demonstrate statistically significant predictive roles of other variables for five-year DFS, as shown in Table 2.

ROC analysis revealed a low discriminatory power of uPA/PAI-1 markers for predicting five-year DFS (AUC = 0.472; p = 0.675; 95% CI: 0.340, 0.605), as depicted in Figure 1.

For patients with a Ki-67 index < 14%, the estimated DFS was 48.08 months, while for those with a Ki-67 index ≥ 14%, it was 44.03 months, with a statistically significant difference demonstrated by the Log-rank test (X^2 = 7.08; p = 0.008). The five-year DFS rate for patients with a Ki-67 index < 14% was 90.2%, while for those with a Ki-67 index ≥ 14%, it was 73.5%, with a statistically significant difference (p = 0.011), as shown in Figure 2A.

No statistically significant difference in estimated DFS was found among patients with different levels of uPA/PAI-1 markers by the Log-rank test (X^2 = 1.706; p = 0.636). The five-year DFS rates for different marker



Figure 1. *ROC Curve for uPA-PAI-1 complex in predicting five-year disease-free survival*

ROC, Receiver operating characteristic; uPA/PAI-1, Urokinase plasminogen activator/plasminogen activator inhibitor-1

levels were as follows: 0-0.99 ng/ml (82.9%), 1-1.99 ng/ml (86.0%), 2-2.99 ng/ml (90.9%), and 3 ng/ml and above (100.0%), with no statistically significant difference (p = 0.623), as shown in Figure 2B.

DISCUSSION

Our study analyzed the prognostic and predictive significance of the Ki-67 proliferation index and preoperative values of the uPA/PAI-1 complex in serum in patients with early invasive breast cancer. Unlike the uPA/PAI-1 complex in serum, the Ki-67 proliferation index proved to be a significant prognostic-predictive factor for DFS in these patients.

Patients with negative estrogen receptors have a statistically significantly higher risk for a shorter DFS, likely due to biologically more aggressive tumors and reduced benefit from hormonal therapy (18, 19, 20). Negative progesterone receptors are also associated with an increased risk of shorter DFS, emphasizing the importance of hormonal signaling (21). The HER-2 hormonal expression system plays a crucial role in therapy selection and response intensity but is associated with a higher risk of unfavorable outcomes (22, 23). Axillary lymph node analysis is crucial for accurately determining disease stage and adjusting therapy, especially in patients with multiple positive lymph nodes (24-27). The Luminal A tumor subtype of breast cancer typically responds positively to hormonal therapy, which may contribute to longer DFS, particular-



Figure 2. *Five-year disease-free survival based on Ki-67 index (A) and uPA-PAI-1 (B) marker levels*

Ki-67, Antigen Kiel 67; uPA/PAI-1, Urokinase plasminogen activator/plasminogen activator inhibitor-1

ly in the first five years (28, 29). Various studies have confirmed that patients with high Ki-67 indices have a greater risk of shorter DFS (30, 31). The Ki-67 index, which measures the rate of tumor cell proliferation, is associated with accelerated cell division and faster tumor growth (32). Reduced sensitivity of these tumors to certain therapeutic protocols can also contribute to an increased likelihood of shorter DFS, as noted in our study (33).

Multivariate regression analysis has demonstrated the association of tumor stage, tumor size, and Ki-67 index with DFS, supporting previous findings regarding their prognostic-predictive significance (34, 35). These factors together reflect the complexity of the disease and its potential impact on outcomes. The Ki-

67 index, as a proliferation marker, further contributes to understanding the disease dynamics (32, 36-39).

The study conducted by Mahmood et al. (40) investigated serum uPA/PAI-1 in the contex to fearly invasive breast cancer, highlighting the need to consider systemic factors in interpreting serum biomarkers and emphasizing the importance of considering potential influences of cytokines and other tumor markers on uPA/PAI-1 complex expression. Additionally, the values of this complex measured in serum do not represent a reliable prognostic and predictive parameter (41), unlike its values in the cytosol or tumor tissue (42, 43, 44).

Limitations of our study include the lack of analysis of the interaction between the Ki-67 index and the uPA/PAI-1 complex, both mutually and with other standard clinicopathological characteristics. Such analysis would enable better identification of patient subsets that could benefit from a combined analysis of these markers. Further more, other genetic or molecular characteristics that could affect the prognostic and predictive significance of these biomarkers were not included (11, 12, 13). The lack of long-term follow-up, as the follow-up only covered the first five postoperative years, is also considered a limitation of the study (45).

Our results indicate a statistically significant effect of elevated Ki-67 values on shortening DFS, with this effect consistent regardless of the presence of uPA/PAI-1 and other previously documented prognostic factors considered in our study.

CONCLUSION

Our study emphasizes the strong and consistent prognostic and predictive ability of the Ki-67 index in assessing DFS in patients who have undergone surgery for early invasive breast cancer. In contrast, preoperative values of the uPA/PAI-1 complex in serum, whether alone or in combination with other predictors, did not show significant prognostic and predictive potential for assessing DFS in these patients. Additional monitoring and tailored therapeutic strategies may be beneficial for patients with elevated Ki-67 values, T2 stage tumors, and tumor sizes of 20-50 mm.

Abbreviations

TNM (Tumor, Node, Metastasis) – tumor classification based on tumor size, lymph node involvement, and the presence of distant metastases

ER – estrogen receptor

HER-2 – human epidermal growth factor receptor 2

Ki-67 – marker of proliferation Ki-67

PR – progesterone receptor

uPA – urokinase plasminogen activator

PAI-1 – plasminogen activator inhibitor 1

DFS – disease-free survival

Conflict of Interests: The authors declare no conflicts of interest related to this article.

Funding: No.

Author contribution: All authors have contributed equally.

Note: Artificial intelligence was not utilized as a tool in this study.

Sažetak

PROGNOSTIČKO-PREDIKTIVNI ZNAČAJ Ki-67 PROLIFERATIVNOG INDEKSA I PREOPERATIVNIH VREDNOSTI uPA/PAI-1 KOMPLEKSA U SERUMU KOD PACIJENTKINJA SA RANIM INVAZIVNIM KARCINOMOM DOJKE

Pušina Sadat,[1] Hodžić Edin,[1] Salibašić Mirhan,[1] Bičakčić Emir,[1] Herenda-Pušina Naida,[2] Halilović Emsad[1]

[1] Klinički centar Univerziteta u Sarajevu, Klinika za opštu i abdominalnu hirurgiju, Sarajevo, Bosna i Hercegovina
[2] Klinički centar Univerziteta u Sarajevu, Klinika za anesteziju i reanimaciju, Sarajevo, Bosna i Hercegovina

Uvod: Karcinom dojke, najčešći malignitet kod žena, predstavlja značajan zdravstveni problem, a biomarkeri poput Ki-67 indeksa i uPA/PAI kompleksa mogu pružiti uvid u ishode lečenja i terapijski odgovor.

Cilj: Glavni ishod studije bila je procena petogodišnjeg preživljavanja bez bolesti (DFS), definisanog kao postoperativno razdoblje do pojave loko-regionalnih ili udaljenih metastaza i smrti od bilo kojeg uzroka.

Materijal i metode: Retrospektivna kohortna studija uključivala je 166 pacijentkinja sa ranim invazivnim karcinomom dojke, kod kojih se procenjivao prognostički i prediktivni značaj uPA/PAI-1 komplek-

sa i Ki-67 biomarkera kod hirurški tretiranih pacijentkinja na Klinici za opštu i abdominalnu hirurgiju Kliničkog centra Univerziteta u Sarajevu, u periodu od septembra 2015 do februara 2017.

Rezultati: Univarijantnom regresionom analizom utvrđena je povećana verovatnoća za DFS kraći od pet godina kod pacijentkinja sa negativnim hormonskim receptorima, pozitivnim HER-2 receptorom, sa ≥ 8 pozitivnih limfnih čvorova i Ki-67 indeksom ≥ 14% ($p < 0.05$). Multivarijantnom regresionom analizom utvrđeno je da su T2 stadijum, veličina tumora od 20-50 mm i Ki-67 indeks ≥ 14% povezani sa većom verovatnoćom za DFS kraći od pet godina ($p < 0.05$). Petogodišnja stopa DFS-a bila je veća kod pacijenata sa Ki-67 indeksom < 14% u odnosu na one sa ≥ 14% ($p = 0.011$), dok nije bilo razlike u petogodišnjem DFS-u među pacijenticama sa različitim nivoima uPA/PAI-1 kompleksa ($p = 0.636$).

Zaključak: Naša studija ističe važnost Ki-67 proliferativnog indeksa kao snažnog prognostičko prediktivnog faktora za DFS kod pacijentkinja operisanih zbog ranog invazivnog karcinoma dojke. Dodatni nadzor i prilagođene terapijske strategije mogu biti korisni kod pacijentkinja sa povišenim vrednostima Ki-67 indeksa, T2 stadijumom i veličinom tumora od 20-50 mm.

Ključne reči: biomarkeri, opšta hirurgija, ishodi lečenja, zdravlje žena.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-49. doi.org/10.3322/caac.21660.

2. Viale PH. The American Cancer Society's Facts & Figures: 2020 Edition. J Adv Pract Oncol. 2020; 11(2): 135-6. doi: 10.6004/jadpro.2020.11.2.1.

3. Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan M, et al. Customizing local and systemic therapies for women with early breast cancer: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021; 32(10): 1216-35. doi: 10.1016/j.annonc.2021.06.023.

4. Zhu H, Doğan BE. American joint committee on cancer's staging system for breast cancer, Eighth edition: summary for clinicians. Eur J Breast Health. 2021; 17(3): 234-8. doi: 10.4274/ejbh.galenos.2021.2021-4-3.

5. Hacking SM, Wang Y. Practical issues of Ki-67 evaluation in breast cancer clinical practice. J ClinTransl Res. 2022; 2(2): 53–6. doi: 10.14218/JCTP.2022.00012.

6. Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in breast cancer working group. J Nat Cancer Inst. 2021; 113(7): 808-19. doi: 10.1093/jnci/djaa201.

7. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009; 101(21): 1446–52. doi: 10.1093/jnci/djp335.

8. Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M. uPA and PAI-1 as biomarkers in breast cancer: Validated for clinical use in level of evidence 1 studies. Breast Cancer Res. 2014; 16(4): 428. doi: 10.1186/s13058-014-0428-4.

9. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33): 5287–312. doi: 10.1200/JCO.2007.14.2364.

10. Fabrice A, Nofisat I, Kimberly HA, Barlow WE, Collyar DE, Damodaran S, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO Guideline update. J Clin Oncol. 2022; 40(16): 1816-37. doi: 10.1200/JCO.22.00069.

11. Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in breast cancer working group. J Natl Cancer Inst. 2021; 113(7): 201. doi: 10.1093/jnci/djaa201.

12. Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, et al. Use of biomarkers to guide decisions on ad juvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2017; 35(24): 2838–47. doi: 10.1200/JCO.2017.74.0472.

13. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol. 2011; 29(32): 4273–8. doi: 10.1200/JCO.2010.31.2835.

14. American Cancer Society. Breast-conserving surgery. Available from:URL:https://www.cancer.org/cancer/types/breast-cancer/treatment/surgery-for-breast-cancer/breast-conserving-surgery-lumpectomy.html (date last accessed: Feb 3, 2024).

15. Pedersen AN, Brünner N, Høyer Hansen G, Hamer P, Jarosz D, Larsen B, et al. Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients. Clin Chem. 1999; 45(8): 1206-13. doi: 10.1093/clinchem/45.8.1206.

16. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Panel members. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011; 22(8): 1736-47. doi: 10.1093/annonc/mdr304.

17. American Cancer Society. Mammograms After Breast Cancer Surgery. Available from: URL:https://www.cancer.org/cancer/types/breastcancer/screening-tests-and-earlydetection/mammograms/having-a-mammogram-after-youve-had-breast-cancer-surgery.html (date last accessed: Feb 2, 2024).

18. Chuanxu L, Xiaorong Z, Yu F, Yanqi W, Hong Z, Ting L. Clinical characteristics and survival outcome of patients with

estrogen receptor low positive breast cancer. Breast. 2022; 63: 24–8. doi.org/10.1016/j.breast.2022.03.002.

19. Belete AM, Aynalem YA, Gemeda BN, Demelew TM, Shiferaw WS. The effect of estrogen receptor status on survival in breast cancer patients in Ethiopia. Retrospective cohort study. Breast Cancer (Dove Med Press). 2022; 14: 153-61. doi: 10.2147/BCTT.S365295.

20. Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol. 2018; 52(Pt1): 56–73. doi: 10.1016/j.semcancer.2017.08.010.

21. Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast cancer—major changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin. 2017; 67(4): 290–303. doi: 10.3322/caac.21393.

22. Van Maaren MC, de Munck L, Strobbe LJA, Sonke GS, Westenend PJ, Smidt ML, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. Int J Cancer. 2019; 144(2): 263–72. doi: 10.1002/ijc.31914.

23. Tonellotto F, Bergmann A, Abrahão KS, Sales de Aguiar S, Adeodato BM, Thuler LCS. Impact of number of positive lymph nodes and lymph node ratio on survival of women with node-positive breast cancer. Eur J Breast Health. 2019; 15(2): 76-84. doi: 10.5152/ejbh.2019.4414.

24. Sopik V, Narod SA. Therelationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer ResTreat. 2018; 70(3): 647-56. doi: 10.1007/s10549-018-4796-9.

25. Lian W, Fu F, Chen D, Wang C. Effect of node status on breast cancer survival by subtype: a single-center retrospective cohort study. Transl Cancer Res. 2020; 9(10): 5900-08. doi: 10.21037/tcr-20-1117.

26. Al- Azawi SM, Al- Khateeb MM, Raoof HS. Correlation between histological grading and size of breast cancer with axillary lymph node involvement, a continuous retrospective and prospective study. Int J Curr Res. 2019; 11(1): 688-92.

27. Zhang X. Molecular classification of breast cancer: relevance and challenges. Arch Pathol Lab Med. 2023; 147(1): 46–51. doi: 10.5858/arpa.2022-0070-RA.

28. Higgins MJ, Stearns V. Understanding resistance to Tamoxifenin hormone receptor-positive breast cancer. Clin Chem. 2009; 55(8): 1453–5.

29. Sean MH, Yihong W. Practical issues of Ki-67 evaluation in breast cancer clinical practice. J Clin Pathol. 2022; 2(2): 53–6. doi: 10.14218/JCTP.2022.00012.

30. Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, et al. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group. J Nat Cancer Inst. 2021; 113(7): 808-19. doi: 10.1093/jnci/djaa201.

31. Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers. 2021; 13(17): 4455. doi: 10.3390/cancers13174455.

32. Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022; 40(16): 1816-37. doi: 10.1200/JCO.22.00069.

33. De Gregorio A, Friedl TWP, Hering E, Widschwendter P, de Gregorio N, Bekes I, et al. Ki67 as proliferative marker in patients with early breast cancer and its association with clinicopathological factors. Oncology. 2020; 99(12): 780–9. doi: 10.1159/000517490.

34. Aman NA, Doukoure B, Koffi KD, Koui BS, Traore ZC, Kouyate M, et al. Immunohistochemical evaluation of Ki-67 and comparison with clinicopathologic factors in breast carcinomas. Asian Pac J Cancer Prev. 2019; 20(1): 73–9. doi: 10.31557/apjcp.2019.20.1.73.

35. Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol 2020; 21(11): 1443-54. doi: 10.1016/S1470-2045(20)30458-7.

36. Gluz O, Kuemmel S, Nitz U, Braun M, Lüdtke-Heckenkamp K, von Schumann R, von Schumann R, et al. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamidein high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial. Ann Oncol. 2023; 34(6): 531-42. doi: 10.1016/j.annonc.2023.04.002.

37. Ma CX, Suman V, Leitch AM, Sanati S, Vij K, Unzeitig GW, et al. Neoadjuvant chemotherapy response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106). Cancer Res. 2021; 81(4): GS4-05. doi: 10.1158/1538-7445.SABCS20-GS4-05.

38. Harbeck N, Johnston S, Fasching P, Martin M, Toi M, Rastogi P, et al. High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarch E. Cancer Res 2021; 81(4): PD2-01.

39. Mahmood N, Mihalcioiu C, Rabbani SA. Multifaceted role of the urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Diagnostic, prognostic, and therapeutic applications. Front Oncol. 2018; 8: 24. doi: 10.3389/fonc.2018.00024.

40. Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, et al. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)- recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer. 2013; 49(8): 1825-35. doi: 10.1016/j.ejca.2013.01.007.

41. Pusina S. Correlation of serum levels of urokinase activation plasminogen (uPA) and its inhibitor (PAI-1) with hormonal and HER-2 status in the early invasive breast cancer. Med Arch. 2018; 72(5): 336-41. doi: 10.5455/medarh.2018.72.335-340.

42. Boissière-Michot F, Mollevi C, Baecker V, Crapez E, Jacot W. In situ hybridization for the assessment of urokinase plasminogen activator and plasminogen activator inhibitor type 1 in formalin fixed paraffin embedded breast cancer specimens. Int J Mol Med. 2022; 49(6): 82. doi: 10.3892/ijmm.2022.5138.

43. Buta M, Džodić R,, Đurišić I, Marković I, Vujasinović T, Markićević M et al. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer

patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.Tumour Biol. 2015; 36(10): 8193-200. doi: 10.1007/s13277-015-3573-1.

44. Singer CF, Filipits M, Jahn SW, Abete L, Jakesz R, Greil R, et al. Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine treated postmenopausal patients with receptor-positive early breast cancer. Breast. 2019; 46: 101-7. doi: 10.1016/j.breast.2019.05.007.

45. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017; 377(19): 1836-46. doi: 10.1056/NEJMoa1701830.

Correspondence to/Autor za korespondenciju
Sadat Pušina
Residential address: Bolnička 25, 71000 Sarajevo
Phone number: +387 33 297 179
E-mail address: sadatpusina1975@gmail.com
ORCID ID: 0000-0002-6380-241X

***How to cite this article**:* Pušina S, Hodžić E, Salibašić M, Bičakčić E, Herenda-Pušina N, Halilović E. The prognostic and predictive value of Ki-67 proliferation index and uPA/PAI-1 complex in serum for patients with early invasive breast cancer. Sanamed. 2024; 19(2): 181-189. Doi: 10.5937/sanamed0-51480.